
Atacicept May Offer Durable Benefits in IgAN with Ongoing Use, with Jonathan Barratt, MD, PhD
Fresh on the heels of ORIGIN phase 3 topline results, new follow-up data from the phase 2b ORIGIN study highlight the consequences of atacicept discontinuation in patients with IgA nephropathy (IgAN), underscoring the potential need for sustained B-cell– …